ALK Rearrangement Non-small Cell Lung Cancer
1 clinical trials · Condition
◉ Watch ALK Rearrangement Non-small Cell Lung Cancer
| Record | Firm | Date |
|---|---|---|
| A Phase I Study of XZP-3621 in Chinese Patients With ALK or ROS1 Rearrangement Non-small Cell Lung Cancer (NCT05055232) | Xuanzhu Biopharmaceutical Co., Ltd. | 2019-03-12 |
Track ALK Rearrangement Non-small Cell Lung Cancer automatically
Every clearance here is in the API, with alerts when new ones post.